Characteristics | Multivariable analysis (clinical and genomic data; n=78) | Multivariable analysis (entire cohort, clinical data only; n=119) | ||
HR (95% CI) | P value | HR (95% CI) | P value | |
Histology (pure UC vs mixed or pure variant histology) | 1.09 (0.32 to 3.74) | 0.89 | 0.91 (0.41 to 2.02) | 0.81 |
ECOG PS ≤1 | 0.38 (0.11 to 1.32) | 0.13 | 0.46 (0.23 to 0.90) | 0.03 |
Visceral metastases | 2.47 (0.73 to 8.33) | 0.14 | 1.89 (0.75 to 4.79) | 0.18 |
BMI | 0.93 (0.84 to 1.02) | 0.14 | 0.98 (0.89 to 1.03) | 0.27 |
Albumin | 0.49 (0.18 to 1.32) | 0.16 | 0.55 (0.30 to 1.01) | 0.05 |
Hemoglobin <100 vs ≥100 g/L | 0.41 (0.1 to 1.75) | 0.23 | 0.82 (0.31 to 2.14) | 0.68 |
NLR <5 vs ≥5 | 1.83 (0.50 to 6.74) | 0.36 | 1.05 (0.51 to 2.15) | 0.90 |
TERT promoter mutation | 0.30 (0.10 to 0.93) | 0.04 | N/A | N/A |
CDKN2B mutation | 1.86 (0.55 to 6.26) | 0.32 | N/A | N/A |
Bold values denote statistical significance at the p < 0.05 level.
BMI, body mass index; ECOG, Eastern Cooperative Oncology Group Performance Status; N/A, not available; NLR, neutrophil to lymphocyte ratio; UC, urothelial carcinoma.